PL2173381T3 - Polipeptydy o zmodyfikowanych funkcjach efektorowych wiążące się z receptorem Fc - Google Patents

Polipeptydy o zmodyfikowanych funkcjach efektorowych wiążące się z receptorem Fc

Info

Publication number
PL2173381T3
PL2173381T3 PL08872467T PL08872467T PL2173381T3 PL 2173381 T3 PL2173381 T3 PL 2173381T3 PL 08872467 T PL08872467 T PL 08872467T PL 08872467 T PL08872467 T PL 08872467T PL 2173381 T3 PL2173381 T3 PL 2173381T3
Authority
PL
Poland
Prior art keywords
receptor
effector functions
binding polypeptides
modified effector
modified
Prior art date
Application number
PL08872467T
Other languages
English (en)
Inventor
Greg Elson
Olivier Leger
Original Assignee
Novimmune Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novimmune Sa filed Critical Novimmune Sa
Publication of PL2173381T3 publication Critical patent/PL2173381T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL08872467T 2007-05-14 2008-05-14 Polipeptydy o zmodyfikowanych funkcjach efektorowych wiążące się z receptorem Fc PL2173381T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93027607P 2007-05-14 2007-05-14
EP08872467.9A EP2173381B1 (en) 2007-05-14 2008-05-14 Fc receptor-binding polypeptides with modified effector functions
PCT/IB2008/003978 WO2009101479A2 (en) 2007-05-14 2008-05-14 Fc receptor-binding polypeptides with modified effector functions

Publications (1)

Publication Number Publication Date
PL2173381T3 true PL2173381T3 (pl) 2014-03-31

Family

ID=40957323

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08872467T PL2173381T3 (pl) 2007-05-14 2008-05-14 Polipeptydy o zmodyfikowanych funkcjach efektorowych wiążące się z receptorem Fc

Country Status (14)

Country Link
US (3) US8546539B2 (pl)
EP (1) EP2173381B1 (pl)
JP (6) JP2010526868A (pl)
CN (1) CN101720232B (pl)
AU (1) AU2008350535B2 (pl)
CA (1) CA2689680C (pl)
DK (1) DK2173381T3 (pl)
ES (1) ES2441189T3 (pl)
IL (1) IL202107A (pl)
MX (1) MX2009012319A (pl)
PL (1) PL2173381T3 (pl)
PT (1) PT2173381E (pl)
SI (1) SI2173381T1 (pl)
WO (1) WO2009101479A2 (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2173381T1 (sl) * 2007-05-14 2014-01-31 Novimmune Sa Fc receptor-vezavni polipeptidi z modificiranimi efektorskimi funkcijami
IE20090514A1 (en) * 2009-07-06 2011-02-16 Opsona Therapeutics Ltd Humanised antibodies and uses therof
WO2012096917A1 (en) 2011-01-10 2012-07-19 Novimmune S.A. Anti-tlr4 antibodies and methods of use thereof
EP2831117B1 (en) 2012-03-29 2017-11-01 NovImmune SA Anti-tlr4 antibodies and uses thereof
WO2015059168A1 (en) 2013-10-22 2015-04-30 Novimmune S.A. Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of tlr4 ligands and other biomarkers
WO2015082716A1 (en) 2013-12-06 2015-06-11 Novimmune S.A. Anti-tlr4 antibodies and methods of use thereof
US20170038381A1 (en) * 2015-08-06 2017-02-09 Novimmune Sa Methods and compositions for identifying patient populations for diagnosis and treatment of tlr4-dependent disorders
WO2018183520A1 (en) * 2017-03-28 2018-10-04 Lyvgen Biopharma Holdings Limited Therapeutic agents and methods for enhancing immune responses in tumor microenvironment
EP3692060A1 (en) * 2017-10-03 2020-08-12 Merck Patent GmbH Cysteine engineered antigen-binding molecules
AR122263A1 (es) * 2019-05-09 2022-08-31 Genentech Inc Métodos para producir anticuerpos
AU2021208630A1 (en) * 2020-01-17 2022-07-21 University Of Tennessee Research Foundation Chimeric antigen receptors for removal of amyloid
EP4138912A4 (en) * 2020-04-20 2024-08-07 Edesa Biotech Research Inc. COMPOSITIONS AND METHODS FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROME
US20240018228A1 (en) * 2020-08-28 2024-01-18 Board Of Regents, The University Of Texas System Antibodies specific to ccl21 and methods of use
CA3264865A1 (en) * 2022-08-16 2024-02-22 University Of Vermont And State Agricultural College ANTIBODIES FOR PLATELET FγRIIA AND ASSOCIATED METHODS OF USE
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025179294A2 (en) 2024-02-22 2025-08-28 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US993904A (en) 1911-02-28 1911-05-30 Ribbon Metals Syndicate Ltd Apparatus for making metal strips, foil, sheets, or ribbons.
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
DE3788058T2 (de) 1986-08-28 1994-04-21 Teijin Ltd Zelltoxischer antikörperkomplex und verfahren zu seiner herstellung.
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP0586505A1 (en) 1991-05-14 1994-03-16 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
ATE335072T1 (de) 1993-05-28 2006-08-15 Scripps Research Inst Methoden für inhibition der cd14-abhängigen zellaktivierung
SI1068241T1 (sl) 1998-04-02 2007-12-31 Genentech Inc Protitelesne variante in njihovi fragmenti
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
ES2292236T3 (es) 1998-04-02 2008-03-01 Genentech, Inc. Variantes de anticuerpos y sus fragmentos.
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7662925B2 (en) * 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
AU2003217912A1 (en) * 2002-03-01 2003-09-16 Xencor Antibody optimization
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
ATE510853T1 (de) 2003-09-23 2011-06-15 Univ Muenchen Tech Tlr2-antagonistischer antikörper und dessen verwendung
US7674884B2 (en) 2003-12-10 2010-03-09 Novimmune S.A. Neutralizing antibodies and methods of use thereof
US7312320B2 (en) 2003-12-10 2007-12-25 Novimmune Sa Neutralizing antibodies and methods of use thereof
EP1711531B9 (en) * 2003-12-10 2012-07-25 Novimmune SA Neutralizing anti tlr4/md-2 antibodies and methods of use thereof
WO2006085967A2 (en) * 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
EP1810035A4 (en) * 2004-11-10 2010-03-17 Macrogenics Inc GENERATION OF FC ANTIBODY REGIONS FOR EFFECTOR FUNCTION
AU2005325482B2 (en) * 2004-12-10 2011-06-16 Novimmune S.A. Combining therapies targeting multiple toll-like receptors and use thereof
CA2602663A1 (en) 2005-03-31 2006-10-05 Xencor, Inc. Fc variants with optimized properties
SI2173381T1 (sl) * 2007-05-14 2014-01-31 Novimmune Sa Fc receptor-vezavni polipeptidi z modificiranimi efektorskimi funkcijami
WO2012096917A1 (en) * 2011-01-10 2012-07-19 Novimmune S.A. Anti-tlr4 antibodies and methods of use thereof
EP2831117B1 (en) * 2012-03-29 2017-11-01 NovImmune SA Anti-tlr4 antibodies and uses thereof

Also Published As

Publication number Publication date
WO2009101479A2 (en) 2009-08-20
MX2009012319A (es) 2010-03-01
CN101720232B (zh) 2013-07-10
JP2020111613A (ja) 2020-07-27
CN101720232A (zh) 2010-06-02
PT2173381E (pt) 2013-12-13
SI2173381T1 (sl) 2014-01-31
US20140038287A1 (en) 2014-02-06
JP2017036333A (ja) 2017-02-16
US20120142098A1 (en) 2012-06-07
WO2009101479A3 (en) 2010-02-25
CA2689680A1 (en) 2009-08-20
CA2689680C (en) 2017-11-07
AU2008350535A1 (en) 2009-08-20
JP6360128B2 (ja) 2018-07-18
IL202107A0 (en) 2011-08-01
JP2014005306A (ja) 2014-01-16
US9688755B2 (en) 2017-06-27
EP2173381B1 (en) 2013-10-02
ES2441189T3 (es) 2014-02-03
IL202107A (en) 2014-05-28
EP2173381A2 (en) 2010-04-14
JP2015017133A (ja) 2015-01-29
JP2018087234A (ja) 2018-06-07
AU2008350535B2 (en) 2013-08-22
DK2173381T3 (da) 2013-12-02
JP2010526868A (ja) 2010-08-05
US20170298129A1 (en) 2017-10-19
US8546539B2 (en) 2013-10-01

Similar Documents

Publication Publication Date Title
PL2173381T3 (pl) Polipeptydy o zmodyfikowanych funkcjach efektorowych wiążące się z receptorem Fc
IL250508A0 (en) Antibody fc mutants with intact effector functions
GB0721686D0 (en) Polypeptides
IL221062A0 (en) Stitched polypeptides
ZA200810738B (en) Polypeptide
IL237314A0 (en) Modified insulin polypeptides and their uses
EP2448972A4 (en) IMMUNOGLOBULIN FC POLYPEPTIDES
IL196889A0 (en) Albumin-insulin fusion proteins
EP2230300A4 (en) POLYPEPTIDE WITH IMPROVED EFFECTOR FUNCTION
ZA201000283B (en) Reinigung pegylierter polypeptide
GB0708376D0 (en) Novel polypeptides and uses thereof
ZA201100847B (en) Insulin fusion polypeptides
GB0712302D0 (en) Chrondroitinase polypeptides
GB0809659D0 (en) Polypeptides
GB0709860D0 (en) The extra hand
GB0623539D0 (en) Polypeptides
GB0700759D0 (en) Novel fusion protein
IL204171A (en) An enzyme strain of the staphylocinase family
GB0610277D0 (en) Pram umbrella unit
AU2007900058A0 (en) Recombinant Antibodies
GB0713169D0 (en) Fusion proteins
GB0709707D0 (en) Novel fusion protein
GB0715413D0 (en) Fusion skyer
GB0715933D0 (en) Fusion snicker
HK1174046A (en) Fusion polypeptides and uses thereof